Cost-effectiveness analysis of pharmacokinetic-driven prophylaxis vs. standard prophylaxis in patients with severe haemophilia A.

Iannazzo, Sergio; Cortesi, Paolo A; Crea, Roberto; Steinitz, Katharina; Mantovani, Lorenzo G; Gringeri, Alessandro

Iannazzo, Sergio; Cortesi, Paolo A; Crea, Roberto; Steinitz, Katharina; Mantovani, Lorenzo G; Gringeri, Alessandro.

Affiliation

Iannazzo S; aFondazione Charta, Milano bResearch Centre on Public Health (CESP), University of Milan-Bicocca, Monza, Italy cBaxalta Innovations GmbH, Vienna, Austria.

Blood Coagul Fibrinolysis ; 28(6): 425-430, 2017 Sep.

Article in En | MEDLINE | ID: mdl-27898515

Subject(s)

Cost-Benefit Analysis; Hemophilia A/economics; Pharmacokinetics; Premedication/methods; Factor VIII/administration & dosage; Factor VIII/economics; Hemarthrosis/economics; Hemarthrosis/prevention & control; Hemophilia A/drug therapy; Humans; Premedication/economics

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Premedication / Pharmacokinetics / Cost-Benefit Analysis / Hemophilia A Type of study: Health_economic_evaluation / Prognostic_studies Limits: Humans Language: En Journal: Blood Coagul Fibrinolysis Journal subject: ANGIOLOGIA / HEMATOLOGIA Year: 2017 Document type: Article Affiliation country: Austria Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google